

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Tavitiya, Sudjaritruk		POSITION TITLE Instructor	
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Chiang Mai University, Thailand	M.D.	2004	Medicine
Chiang Mai University, Chiang Mai, Thailand	Diploma	2008	Pediatrics
Chiang Mai University, Chiang Mai, Thailand	Diploma	2010	Pediatric Infectious Disease

NOTE: The Biographical Sketch may not exceed four pages. Items A and B (together) may not exceed two of the four-page limit. Follow the formats and instructions on the attached sample.

A. Positions and Honors. Positions and Employment

- 2005-2007 Resident in Pediatrics, Department of Pediatrics, Chiang Mai University, Thailand
 2008-present Clinical Fellowship in Pediatric Infectious Disease, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Thailand
 2008-present Study physician, Research Institute for Health Sciences, Chiang Mai University, Thailand
 2008-present Lecturer, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Thailand
 2010-present Co-investigator, Research Institute for Health Sciences, Chiang Mai University, Thailand

Other Experience and Professional Memberships

- 2004-present Member of the Medical Council of Thailand
 2007 Fogarty International Clinical Scholars Program (NIH, Bethesda, MD, US.)
 2008-present Membership of The Royal College of Pediatricians of Thailand
 2009 International AIDS Society, Cape Town, South Africa
 2009-present Membership of the Pediatric Infectious Disease Society of Thailand
 2010 Conference of Retrovirus and Opportunistic infections (Young Investigator), San Francisco, California, US.

B. Selected peer-reviewed publications (in chronological order).

- Seewijee T, **Sudjaritruk T**, Oberdorfer P. Atypical pneumonia: diagnosis and treatment. *Thai J Pediatr* 2009;48:193-199.
- Sudjaritruk T**, Udornpornwattana S, Gromrat P, Oberdorfer P. Relapse neonatal HSV infection: 1 case report. *Thai J Pediatr* 2009;48:325-31.
- Makonkawkeyoon K, **Sudjaritruk T**, Sirisanthana V, Silvilairat S. Fulminant enterovirus 71 infection: case report. *Annual Tropical Pediatrics* 2010;30(3):245-8.
- Sudjaritruk T**, Sirisanthana T, Sirisanthana V. Antibody responses to hepatitis A virus vaccination in Thai HIV-infected children with immune recovery after antiretroviral therapy. *Pediatr Inf Dis J* 2011 (in press).
- Sudjaritruk T**, Sirisanthana V. Successful treatment of a child with vascular pythiosis. *BMC Infectious Diseases* 2011, 11:33.

C. Presentation

- Sudjaritruk T**, Sirisanthana V. Successful treatment of vascular pythiosis: A case report. Oral presentation at 67th Annual Pediatrics meeting, April 8 -10,2009, Chonburi, Thailand.

2. **Sudjaritruk T**, Sirisanthana V. Causes of hospitalization in 880 HIV-infected children: effect of Thailand's national antiretroviral access program. Poster Presentation at 1st International Workshop on HIV Pediatrics, 17 – 18 July 2009, Cape Town, South Africa.
3. **Sudjaritruk T**, Aurbibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Causes of hospitalization in 1,112 HIV-infected children: comparison of the pre-*Pneumocystis jirovecii* pneumonia (PCP) prophylaxis, pre-antiretroviral therapy, and antiretroviral therapy (ART) era. Poster Presentation at 17th Conference on Retroviruses and Opportunistic Infections, February 16-19 2010, San Francisco, US.
4. **Sudjaritruk T**, Sirisanthana T, Sirisanthana V. Antibody Responses to Hepatitis A Virus Vaccination in Thai HIV-infected Children with Immune Recovery after Antiretroviral Therapy. Oral Presentation at 14th Annual meeting of Pediatric Infectious Disease Society of Thailand, May 14-16, 2010, Chonburi, Thailand.
5. **Sudjaritruk T**, Sirisanthana T, Sirisanthana V. Antibody Responses to Hepatitis A Virus Vaccination in Thai HIV-infected Children with Immune Recovery after Antiretroviral Therapy. Poster Presentation at 1st International Workshop on HIV Pediatrics, July 16-17, 2010, Vienna.
6. **Sudjaritruk T**, Sirisanthana T, Sirisanthana V. Antibody Responses to Hepatitis A Virus Vaccination in Thai HIV-infected Children with Immune Recovery after Antiretroviral Therapy. Poster Presentation at XVIII International AIDS Conference, July 18-23 2010, Vienna.

D. Research Support.

On Going Research Support

1. **The clinical presentation, diagnosis, management and outcome of tuberculosis in HIV-infected children in the TREAT Asia Pediatric HIV Observational Database (TApHOD)**
Role: Lead Investigator
2. **TASER-Pediatrics: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children**
Role: Site Principle Investigator
3. **Efficacy and Safety of Monovalent Influenza A (H1N1) 2009 Panenza™ in HIV-Infected Thai Children**
Role: Site Principle Investigator
4. **IMPAACT P1083**: A Phase II/III trial of lopinavir/ritonavir dosed according to the WHO pediatric weight band dosing guidelines.
Role: Co-investigator
5. **IMPAACT 1077HS**: HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere).
Role: Study physician
6. **IMPAACT P1026s**: Pharmacokinetic properties of antiretroviral drugs during pregnancy.
Role: Study physician
7. **HIVNAT 121**: A prospective study to compare brain volumes and Diffusion Tensor Imaging (DTI) in HIV-infected children from the immediate compared to deferred antiretroviral therapy arms of PREDICT and to HIV-negative healthy children.
Role: Study physician
8. **A4001031**: An open-label, Multicenter, Multiple-dose pharmacokinetic and 48 weeks safety and efficacy trial of maraviroc in combination with optimized background therapy for the treatment of antiretroviral-experience CCR5-tropic HIV-1 infected children 2-18 years of age.
Role: Study physician
9. **AI424397**: A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the **PRINCE I** Study)
Role: Study physician

Principal Investigator/Program Director (Last, First, Middle): **Sirisanthana, Thira**

- 10. TDF:** Pharmacokinetic study and safety monitoring of tenofovir including once daily antiretroviral regimen in HIV-infected children with viral suppression.
Role: Study physician